April 12, 2012Journal of Hypertension
Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis
Key result
In mild-to-moderate hypertensive patients, visit-to-visit blood pressure variability did not differ substantially between calcium antagonist and beta-blocker treatment over 4 years.
Why the study?
Does lacidipine compared to atenolol reduce visit-to-visit blood pressure variability in mild-to-moderate hypertensive patients?
Population
Mild-to-moderate hypertensive patients from the European Lacidipine Study on Atherosclerosis (ELSA) trial
Comparison
Lacidipine (calcium antagonist) for 4 years vs Atenolol (beta-blocker) for 4 years
Design
Cohort
Follow-up
4 years
Authors
Discussion
Loading...
Member takes
Implication
Similar BP variability effects with these agents in mild hypertension; leaves open impact on outcomes or treatment selection.
Study Design
Type
RCT
Multicenter
Yes
Structured PICO
Does lacidipine compared to atenolol reduce visit-to-visit blood pressure variability in mild-to-moderate hypertensive patients?
P
Population
Mild-to-moderate hypertensive patients from the European Lacidipine Study on Atherosclerosis (ELSA) trial treated for 4 years with either atenolol or lacidipine.
I
Intervention
Lacidipine (calcium antagonist) for 4 years
C
Comparator
Atenolol (beta-blocker) for 4 years
O
Outcome
Visit-to-visit intraindividual variations of both clinic and 24-h mean blood pressure (coefficient of variation of average systolic or diastolic values)surrogate
In mild-to-moderate hypertension, visit-to-visit blood pressure variability does not differ substantially between beta-blocker and calcium antagonist treatments.
Cite This Study
Mancia et al. (2012) conducted an RCT in Mild-to-moderate hypertension. Lacidipine (calcium antagonist) vs. Atenolol (beta-blocker) was evaluated on Visit-to-visit intraindividual variations of clinic and 24-h mean blood pressure. In mild-to-moderate hypertensive patients, visit-to-visit blood pressure variability did not differ substantially between calcium antagonist and beta-blocker treatment over 4 years.